Send and receive information on adverse drug reactions (ADRs)

Information

Type

Guidance

Regulated products

Medical Devices

Topics

Health And Social Care

Published

December 18, 2014

Last updated

May 9, 2024

Description

How marketing authorisation holders should inform MHRA of a signal or an ADR to a medicine.

Organization

Country / Region

United Kingdom

License

Open Government Licence 2.0 (United Kingdom)

Feedback

Suggest an improvement to this page

Actions

Social networks

Embed